Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fred Thomas

Internal Medicine Hampton, VA Medical Doctor

NPI 1518958420 CMS profile 159665

2205 Executive Dr Ste A, Hampton, VA 23666

Open in the dashboard

General payments

$4,960

292 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fred Thomas of Hampton, VA is reported in the CMS Open Payments database as having received $4,960 across 292 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $487 26
2024 General $355 18
2023 General $624 35
2022 General $698 40
2021 General $1,378 79
2020 General $744 45
2019 General $675 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fred Thomas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Fred Thomas were reported at $487. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Fred Thomas Internal Medicine median Middle half National median
2019 $675 $159 $48–$570 $163
2020 $744 $119 $33–$402 $114
2021 $1,378 $135 $37–$521 $132
2022 $698 $141 $42–$496 $149
2023 $624 $149 $45–$519 $160
2024 $355 $154 $47–$537 $164
2025 $487 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $724 43 payments
  2. Novo Nordisk Inc $612 38 payments
  3. GlaxoSmithKline, LLC. $490 30 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $485 26 payments
  5. AstraZeneca Pharmaceuticals LP $440 27 payments
  6. Pfizer Inc. $392 20 payments
  7. Lilly USA, LLC $297 21 payments
  8. Biohaven Pharmaceuticals, Inc. $208 10 payments
  9. Merck Sharp & Dohme Corporation $196 13 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $187 7 payments
  11. Other $929 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,919 290 payments
  2. Education $41 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $606 35 payments
  2. Ozempic $498 31 payments
  3. NURTEC ODT Primary Care $395 17 payments
  4. TRELEGY ELLIPTA $386 23 payments
  5. FARXIGA $312 19 payments
  6. RYBELSUS $307 18 payments
  7. JARDIANCE $279 15 payments
  8. QULIPTA $241 16 payments
  9. TRULICITY $232 17 payments
  10. NURTEC ODT Pain $201 9 payments
  11. Other $3,566 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

3,130

Median for Internal Medicine: 777

Drug cost

$340,215

Median for Internal Medicine: $73,373

Branded share of claims

25%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 54 $55,174
Ozempic Semaglutide Brand 48 $51,112
Trulicity Dulaglutide Brand 35 $39,047
Januvia Sitagliptin Phosphate Brand 44 $37,046
Jardiance Empagliflozin Brand 27 $32,621
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $26,948
Eliquis Apixaban Brand 27 $19,361
Farxiga Dapagliflozin Propanediol Brand 23 $13,155
Mounjaro Tirzepatide Brand 11 $11,295
Entresto Sacubitril/Valsartan Brand 12 $9,815

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$110,695

Of which drugs: $2,973

Medicare patients

225

Average age 76

Services billed

3,894

106 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 42%
Arthritis 41%
Chronic kidney disease 36%
Ischemic heart disease 21%
Atrial fibrillation 17%
Cancer 16%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 20 20 $1,636

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $41
$41 — —
Ozempic
  • Novo Nordisk Inc $41
$41 48 —
UBRELVY
  • AbbVie, Inc. $37
$37 — —
QULIPTA
  • AbbVie, Inc. $37
$37 — —
NURTEC ODT
  • PFIZER INC. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

292 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record